Penumbra, which is set to become part of Boston Scientific this year, is running the trial to inform the treatment of a type of medium-vessel blockage.

Penumbra expands clinical research through the FORWARD stroke study while remaining part of the NYSE Composite with advanced ...

Boston Scientific, Medtronic and Stryker were among the companies to ink deals to move into markets that are expanding ...

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an ...

Penumbra, Inc. announced the initiation of its FORWARD study, which will collect safety and efficacy data on mechanical ...

A look at Penumbra, DexCom and Repligen as medical device and life-science names draw attention amid steady healthcare demand and cautious market sentiment.

Launches Indigo® System Lightning™ 12 in U.S. Appoints Corey L. Teigen, M.D., as Chief Scientific Officer and James F. Benenati, M.D., FSIR, as Chief Medical Officer Lightning™ 12 – Intelligent ...

Physicians in Europe now have access to Penumbra’s most advanced mechanical thrombectomy technology available, which has had a significant impact on patients in the U.S. Designed for single session ...

Shares of Penumbra were sliding after short-seller Quintessential Capital Management released another critical report on the company. The firm first began targeting Penumbra in November. The ...

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world ...